Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Essure Actions Draw Lawmaker Ire, Demand For Product Withdrawal

This article was originally published in The Gray Sheet

Executive Summary

While FDA has gone beyond an advisory committee recommendation to require a registry to monitor Bayer's Essure permanent contraception device, lawmakers say the agency's call for a new postmarket study and black box labeling requirements spelled out in a draft guidance are insufficient to address serious concerns with safety.

You may also be interested in...



FDA 'Black Box' Labeling For Essure Highlights Adverse Events With Bayer Sterility Device

A US FDA final guidance on hysteroscopically placed tubal implant permanent sterilization devices calls for a "black box" warning, pointing out perforation, pain, allergic reactions and other potential adverse events uncovered for Bayer's Essure device. It emphasizes the importance for physicians to employ a patient-decision checklist with the products.

Six-Year Study Will Compare Bayer’s Essure With Tubal Ligation

US FDA has accepted a post-approval study plan by Bayer HealthCare for its Essure permanent sterilization device, which is under intense scrutiny in response to adverse events and charges of clinical trial misconduct. The protocol entails a non-randomized, six-year cohort study comparing Essure-implanted women to tubal ligation sterilization subjects.

Essure Panel Stresses Need For Patient Follow-Up, But Stressed-Out Patients Say, ‘Recall It’

An FDA advisory panel recommended a collection of activities to mitigate risk in the use of Bayer Healthcare’s Essure permanent contraceptive device, but dozens of patients describing hypersensitivity, extreme pain, insert migration, irregular bleeding, ectopic pregnancy and perforation events urged FDA to recall the device.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel